Partnered drug programs
BioArctic develops antibody medicines for brain diseases and works with larger drug companies to take them through testing and approval. Its best-known work is in Alzheimer’s disease, where it helped create lecanemab wit...
Decide at what price you'd be comfortable buying and we'll help you stay ready.
BioArctic is a Swedish drug company focused on treatments for neurodegenerative diseases, especially Alzheimer’s disease and Parkinson’s disease. It does not run a broad consumer business; instead, it discovers and develops medicines and then partners with larger pharmaceutical companies to test, manufacture, and sell them. Its best-known work is around antibody-based drugs that target harmful proteins in the brain.
The company makes money mainly through research payments, milestone payments, and royalties tied to partner-led drug programs. In practice, BioArctic earns income when a partner advances one of its drug candidates, wins approvals, or sells the medicine in the market. That makes it more of a research-and-license business than a traditional drug maker with its own large sales force.
What makes BioArctic different is its strong focus on hard-to-treat brain diseases and its role as an inventor rather than a full commercial pharmaceutical company. It helps create the science and drug candidates, while bigger partners handle late-stage development and global distribution. For investors, the key idea is that BioArctic’s value comes from its pipeline and from how well its partnered medicines perform in the market.
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
New to Alpha Spread? Create free account
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Already have an account? Sign in
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more